Abstract

The most typical benign uterine tumour is a leiomyoma, which is also the most typical pelvic tumour in females.1 Every fourth or fifth woman of reproductive age experiences it. Unfortunately, symptomatology is still inconsistent. The number, size, and location of the tumour are thought to affect the symptomatology, although most leiomyomas are thought to be asymptomatic and advance slowly.2 Objectives To study 100 cases of fibroid uterus with respect to: 1. Clinical spectrum. 2. Pathological correlation, with type of fibroid endometrial and ovarian changes. 3. Associated conditions (medical and surgical co-morbidities). Material & Methods Study Design: Descriptive Cross sectional study. Study area: Department of Obstetrics & Gynaecology, Shimoga Institute of Medical Sciences, Shivamogga. Study Period: April 2017 - March 2018. Study population: Cases of fibroid uterus. Sample size: Study consist a total of 100 subjects. Study tools and Data collection procedure: On admission, a detailed history, clinical examination and investigations were made. The following points were noted in the history. 1. Age and socio-economic status of the patient. 2. History of presenting complaints was taken in detail: noting down the following: (i) Menstrual disorder (detailed menstrual history is taken) Menorrhagia / Metrorrhagia / Polymenorrhea / Dysmenorrhea / Postmenopausal bleeding. (ii) White discharge per vagina – amount, duration, whether blood stained. Results: White discharge per vaginum was seen in 6% of the cases, which was most commonly associated with chronic cervicitis, also seen in cases of fibroid polyp and prolapse. Pain abdomen was seen in 41% of the cases, in most of the cases pain was associated with cystic ovaries, in others pain was due to endometriosis, PID, urinary tract infection or cholelithiasis. Presence of a mass was complained in 8% of the cases. Urinary problems were noticed in 2% of the cases, which was typically associated with cervical fibroid / broad ligament fibroid. Conclusion: In conclusion the emerging drugs like SERMs and SPRMs must be available throughout the tertiary centres as most of the patients are from low socioeconomic background and cannot afford the drugs. LNG IUS also continues to be out of reach for most of these women as it needs regular follow up

Description